E.J. Lawitz

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

Guadalupe García–Tsao, Jaime Bosch, Zeid Kayali et al. · Journal of Hepatology · 2019 · 156 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +14

13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY

Stanislas Pol, Jeroen Aerssens, Stefan Zeuzem et al. · Journal of Hepatology · 2011 · 71 citations

Pharmacy, Internal Medicine, Pharmacotherapy +12

845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY

Jacob Lalezari, David R. Nelson, Robert H. Hyland et al. · Journal of Hepatology · 2013 · 57 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS

E. Schiff, F. Poordad, Ira M. Jacobson et al. · Journal of Hepatology · 2008 · 49 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

Stefan Zeuzem, S. Arora, B. Bacon et al. · Journal of Hepatology · 2011 · 46 citations

Pharmacy, Infectious Diseases, Hepatitis Pharmacotherapy +11